m (Protected "Botulinum toxin" ([Edit=Allow only autoconfirmed users] (expires 22:23, 1 August 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 22:23, 1 August 2014 (UTC))))
|pregnancy_AU=<!-- A / B1 / B2 / B3 / C / D / X -->
|pregnancy_US=<!-- A / B / C / D / X -->
=====Condition2=====
|pregnancy_category=
|legal_AU=<!-- Unscheduled / S2 / S4 / S8 -->
* Dosing Information
|legal_UK=<!-- GSL / P / POM / CD -->
|legal_US=<!-- OTC / Rx-only --> Rx-Only
:* Dosage
=====Condition3=====
* Dosing Information
:* Dosage
=====Condition4=====
* Dosing Information
:* Dosage
<!--Off-Label Use and Dosage (Adult)-->
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
* Developed by:
* Class of Recommendation:
* Strength of Evidence:
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Pediatric Indications and Dosage-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
<!--Off-Label Use and Dosage (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
* Developed by:
* Class of Recommendation:
* Strength of Evidence:
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Contraindications-->
|contraindications=* Condition1
<!--Warnings-->
|warnings=* Description
====Precautions====
* Description
<!--Adverse Reactions-->
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
=====Body as a Whole=====
=====Cardiovascular=====
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
=====Neurologic=====
=====Respiratory=====
=====Skin and Hypersensitivy Reactions=====
=====Special Senses=====
=====Urogenital=====
=====Miscellaneous=====
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
=====Body as a Whole=====
=====Cardiovascular=====
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
=====Neurologic=====
=====Respiratory=====
|routes_of_administration= IM (approved),SC, intradermal, into glands
}}
{{SI}}
{{CMG}}
==Overview==
=====Skin and Hypersensitivy Reactions=====
'''Botulinum toxin''' is a [[neurotoxin]] [[protein]] produced by the bacterium ''[[Clostridium botulinum]]''. It is one of the most poisonous naturally occurring substances in the world, and it is the most toxic protein.<ref>{{cite journal |author=Montecucco C, Molgó J |title=Botulinal neurotoxins: revival of an old killer |journal=Current opinion in pharmacology |volume=5 |issue=3 |pages=274-9 |year=2005 |pmid=15907915 |doi=10.1016/j.coph.2004.12.006}}</ref> Though it is highly toxic, it is used in minute doses both to treat painful muscle spasms, and as a cosmetic treatment in some parts of the world. It is sold commercially under the brand names '''Botox''' and '''Dysport''' for this purpose. The terms Botox and Dysport are trade names and are not used generically to describe the neurotoxins produced by the clostridia species.
==History==
The German physician and poet Justinus Kerner called botulinum toxin "sausage poison", or "Canadian bacon pathogen" as this bacterium often causes poisoning by growing in badly handled or prepared meat products. He first conceived a possible therapeutic use of botulinum toxin. In 1870, Muller (another German physician) coined the name [[botulism]], from [[Latin]] ''botulus'' = "sausage". In 1895, Emile Van Ermengem first isolated the bacterium ''Clostridium botulinum''. In 1944, Edward Schantz cultured ''Clostridium botulinum'' and isolated the toxin, and, in 1949, Burgen's group discovered that botulinum toxin blocks neuromuscular transmission.
By 1973, Alan B Scott, MD, of [[Smith-Kettlewell Institute]] used botulinum toxin type A (BTX-A) in monkey experiments, and, in 1980, he officially used BTX-A for the first time in humans to treat [[strabismus]]. In December 1989, BTX-A (BOTOX) was approved by the US [[Food and Drug Administration]] (FDA) for the treatment of strabismus, [[blepharospasm]], and hemifacial spasm in patients over 12 years old. The cosmetic effect of BTX-A was initially described by ophthalmologist Jean Carruthers and dermatologist Alastair Carruthers, a husband-and-wife team working in Vancouver, Canada, although the effect had been observed by a number of independent groups. On April 15, 2002, the FDA announced the approval of botulinum toxin type A (BOTOX Cosmetic) to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines). BTX-A has also been approved for the treatment of excessive underarm sweating. The acceptance of BTX-A use for the treatment of [[spasticity]] and muscle pain disorders is growing, with approvals pending in many European countries and studies on headaches (including [[migraine]]), [[prostatic]] symptoms, [[asthma]], obesity and many other possible indications are ongoing.
=====Special Senses=====
Botox is manufactured by Allergan Inc (U.S.) for both therapeutic as well as cosmetic use. The formulation is best stored at cold temperature of 2-8 degrees Celsius. Dysport is a therapeutic formulation of the type A toxin developed and manufactured in the UK and which is licenced for the treatment of focal dystonias and certain cosmetic uses in many territories world wide.
Botulinum Toxin Type B (BTX-B) received FDA approval for treatment of cervical [[dystonia]] on December 21, 2000. Trade names for BTX-B are Myobloc in the United States, and Neurobloc® in the European Union.
==Medical uses==
=====Urogenital=====
Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type A decreased muscle activity by blocking the release of [[acetylcholine]] at the [[neuromuscular junction]], thereby rendering the muscle unable to contract for a period of 4 to 6 months.
Alan Scott, a San Francisco [[ophthalmologist]], first applied tiny doses of the toxin in a medicinal sense to treat [[crossed eyes]] and [[uncontrollable blinking]], but needed a partner to gain regulatory approval to market his discovery as a drug. Allergan, Inc., a pharmaceutical company that focused on prescription eye therapies and contact lens products, bought the rights to the drug in 1988 and received FDA approval in 1989. Allergan renamed the drug Botox.
Cosmetically desirable effects of Botox were quickly discovered thereafter when the frown lines between the eyebrows were observed to soften following treatment for eye muscle disorders, leading to clinical trials and subsequent FDA approval for cosmetic use in April 2002. As of 2006, Botox injection is the most common cosmetic operation in the United States. <!-- per "Pots of Promise -->
=====Miscellaneous=====
Besides its cosmetic application, Botox is used in the treatment of
*[[migraine]] headaches
*cervical [[dystonia]] (a neuromuscular disorder involving the head and neck)<ref>{{cite journal | author=Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M | title=Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia | journal=Neurology | year=1999 | pages=1431-8 | volume=53 | issue=7 | id=PMID 10534247}}</ref>
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
*[[blepharospasm]] (involuntary contraction of the eye muscles)<ref> {{cite journal |author=Shukla HD, Sharma SK |title=Clostridium botulinum: a bug with beauty and weapon |journal=Crit. Rev. Microbiol. |volume=31 |issue=1 |pages=11-8 |year=2005 |pmid=15839401 |doi= }}</ref>
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
*severe primary axillary [[hyperhidrosis]] (excessive sweating)<ref>{{cite journal |author=Eisenach JH, Atkinson JL, Fealey RD |title=Hyperhydrosis: evolving therapies for a well-established phenomenon |journal=Mayo Clin. Proc. |volume=80 |issue=5 |pages=657-66 |year=2005 |pmid=15887434 |doi=}}</ref>
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
*[[achalasia]] (failure of the lower esophageal sphincter to relax)
<!--Administration and Monitoring-->
|administration=* Oral
Other uses of botulinum toxin type A that are widely known but not specifically approved by FDA include treatment of:
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
*involuntary microexpression facial triggers (concealing a lie)
* Description
*pediatric incontinence<ref>{{cite journal |author=Schurch B, Corcos J |title=Botulinum toxin injections for paediatric incontinence |journal=Current opinion in urology |volume=15 |issue=4 |pages=264-7 |year=2005 |pmid=15928517 |doi=}}</ref>, incontinence due to overactive bladder,<ref name="pmid17636801">{{cite journal
<!--IV Compatibility-->
| author = Duthie J, Wilson D, Herbison G, Wilson D
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
| title = Botulinum toxin injections for adults with overactive bladder syndrome.
| journal =
| volume = 3
| issue =
| pages = CD005493
| year = 2007
| pmid = 17636801
| doi = 10.1002/14651858.CD005493.pub2
| issn =
}}</ref> and incontinence due to [[neurogenic bladder]].<ref name="pmid17532858">{{cite journal
| author = Akbar M, Abel R, Seyler TM, Gerner HJ, Möhring K
| title = Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
| journal = BJU Int.
| volume = 100
| issue = 3
| pages = 639-45
| year = 2007
| pmid = 17532858
| doi = 10.1111/j.1464-410X.2007.06977.x
| issn =
}}</ref>
*[[anal fissure]]<ref>{{cite journal |author=Trzciński R, Dziki A, Tchórzewski M |title=Injections of botulinum A toxin for the treatment of anal fissures |journal=The European journal of surgery = Acta chirurgica |volume=168 |issue=12 |pages=720-3 |year=2002 |pmid=15362583 |doi=}}</ref>
<!--Overdosage-->
|overdose====Acute Overdose===
*spastic disorders associated with injury or disease of the [[central nervous system]] including trauma, [[stroke]], [[multiple sclerosis]], [[Parkinson's disease]], or [[cerebral palsy]]
====Signs and Symptoms====
*focal [[dystonia]]s affecting the limbs, face, jaw, or [[vocal cords]]
* Description
*[[Temporomandibular joint|TMJ]] pain disorders
====Management====
*diabetic neuropathy
* Description
*wound healing
===Chronic Overdose===
*excessive salivation
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
*VCD (Vocal Cord Dysfunction) a spasming of the vocal cords
<!--Pharmacology-->
*Reduction of the Masseter muscle for decreasing the size of the lower jaw
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
In the ''Journal of Dermatologic Surgery'', Eric Finzi claims to have treated clinically depressed patients with botox. On ''Good Morning America'', he claimed that by taking away the ability to frown, he was somehow taking away the ability to feel depressed.<ref>{{cite web |url=http://i.abcnews.com/GMA/Health/story?id=2003009&page=1 |title=ABC News: Can Botox Cure Depression? |accessdate=2007-08-14 |format= |work=}}</ref>
<!--Structure-->
|structure=*
Treatment and prevention of chronic headache<ref>{{cite journal |author=Panicker JN, Muthane UB |title=Botulinum toxins: pharmacology and its current therapeutic evidence for use |journal=Neurology India |volume=51 |issue=4 |pages=455-60 |year=2003 |pmid=14742921 |doi= |url=http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2003;volume=51;issue=4;spage=455;epage=460;aulast=Muthane
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
}}</ref> and chronic musculoskeletal pain<ref>{{cite journal |author=Charles PD |title=Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses |journal=American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists |volume=61 |issue=22 Suppl 6 |pages=S11-23 |year=2004 |pmid=15598005 |doi=}}</ref> are emerging uses for botulinum toxin type A. In addition, there is evidence that Botox may aid in weight loss by increasing the gastric emptying time.<ref>{{cite journal |author=Coskun H, Duran Y, Dilege E, Mihmanli M, Seymen H, Demirkol MO |title=Effect on gastric emptying and weight reduction of botulinum toxin-A injection into the gastric antral layer: an experimental study in the obese rat model |journal=Obesity surgery : the official journal of the American Society for Bariatric Surgery and of the Obesity Surgery Society of Australia and New Zealand |volume=15 |issue=8 |pages=1137-43 |year=2005 |pmid=16197786 |doi=10.1381/0960892055002275}}</ref>
==Side effects==
<!--Pharmacodynamics-->
Side effects can be predicted from the mode of action (muscle paralysis) and chemical structure (protein) of the molecule, resulting broadly speaking in two major areas of side effects: paralysis of the wrong muscle group and allergic reaction. Bruising at the site of injection is a side effect not of the toxin, but rather the mode of administration. In cosmetic use, this means that the client will complain of inappropriate facial expression such as drooping eyelid, uneven smile, loss of ability to close the eye. This will wear off in around 6 weeks. Bruising is prevented by the clinician applying pressure to the injection site, but may still occur, and will last around 7 - 10 days. When injecting the masseter muscle of the jaw, loss of muscle function will result in a loss or reduction of power to chew solid foods. All cosmetic treatments are of limited duration, and can be as short a period as six weeks, but usually one reckons with an effective period of between 3 and 6 months. At the extremely low doses used medicinally, botulinum toxin has a very low degree of toxicity.
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
==Chemical overview==
<!--Pharmacokinetics-->
There are seven serologically distinct toxin types, designated A through G; 3 subtypes of A have been described. The toxin is a two-chain [[polypeptide]] with a 100-[[dalton (unit)|kDa]] heavy chain joined by a [[disulfide bond]] to a 50-kDa light chain. This light chain is an enzyme (a [[protease]]) that attacks one of the fusion proteins (SNAP-25, syntaxin or synaptobrevin) at a [[neuromuscular junction]], preventing [[vesicle (biology)|vesicle]]s from anchoring to the [[cell membrane|membrane]] to release [[acetylcholine]]. By inhibiting acetylcholine release, the toxin interferes with nerve impulses and causes flaccid (sagging) paralysis of muscles in [[botulism]] as opposite to the spastic paralysis seen in tetanus.
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
It is possibly the most acutely toxic substance known, with a [[LD50|median lethal dose]] of about 1 ng/kg<ref> By Diane O. Fleming, Debra Long Hunt. ''Biological Safety: principles and practices''. ASM Press, '''2000''', p. 267.</ref>, meaning that a few hundred grams could theoretically kill every human on earth (for perspective, the rat poison [[strychnine]], often described as highly toxic, has an [[LD50|LD<sub>50</sub>]] of 1,000,000 ng/kg, and it would take four hundred tons to kill every human).
It is also remarkably easy to come by: ''Clostridium'' spores are found in soil practically all over the earth.
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
Food-borne botulism usually results from ingestion of food that has become contaminated with spores (such as a perforated can) in an anaerobic environment, allowing the spores to germinate and grow. The growing (vegetative) bacteria produce toxin. It is the ingestion of preformed toxin that causes [[botulism]], not ingestion of the spores or vegetative organism.
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
Infant (intestinal) and wound botulism both result from infection with spores which subsequently germinate, resulting in production of toxin and the symptoms of botulism.
The toxin itself is rapidly destroyed by heat, such as in thorough cooking.<ref>[http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=546888&pageindex=3 Thermal inactivation of Botulinum toxin]</ref> However, the spores which produce the toxin are heat-tolerant and will survive boiling at 100 degrees Celsius for an extended period of time.
<!--How Supplied-->
|howSupplied=*
==Chemical warfare==
<!--Patient Counseling Information-->
Botulin toxin has always been considered an inferior agent for [[chemical warfare]] since it degrades rapidly on exposure to air, and therefore an area attacked with the toxic [[particulate|aerosol]] would be safe to enter within a day or so. In fact, the agent is so unstable that the medicinal form is generally shipped on dry ice. There are no documented cases of the toxin actually being used in warfare; however, it has been claimed to have been used in the Operation Anthropoid to kill top Nazi Reinhard Heydrich<ref>{{cite web |url=http://www.strategypage.com/articles/biotoxin_files/BIOTOXINASSASINATION.asp |title=StrategyPage.com - Medium Brigade Flaws, and the Cure The IBCT Revisited |accessdate=2007-08-14 |format= |work=}}</ref> and in "Operation Mongoose", where in 1961, the CIA saturated some cigars, of Fidel Castro's favorite brand, with botulinum toxin for a possible assassination attempt. The cigars were never used, but when tested years later were found still effective.<ref>{{cite web |url=http://www.parascope.com/mx/articles/castroreport.htm |title=parascope.com - Castro report |accessdate=2007-08-14 |format= |work=}}</ref> The notorious Japanese biological warfare group Unit 731 fed botulinum to prisoners during Japan's occupation of Manchuria in the 1930s.<ref>{{cite web |url=http://jama.ama-assn.org/cgi/content/full/285/8/1059 |title=JAMA -- Botulinum Toxin as a Biological Weapon: Medical and Public Health Management, February 28, 2001, Arnon et al. 285 (8): 1059 |accessdate=2007-08-14 |format= |work=}}</ref>
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
There has been concern over the use of botulin toxin as a terrorist weapon, but it appears not to be ideal for this purpose. The vials used therapeutically are considered impractical as weapons because each vial contains only an extremely small fraction of the lethal dose. Nor is home-growing very viable; the bacterium in question is [[anaerobic organism|anaerobic]] and grows poorly in the presence of oxygen. This would make it difficult for terrorists to produce the toxin in bulk without specialized microbiological expertise.
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
The toxin's properties did not escape the attention of the Aum Supreme Truth cult in Japan, who had set up a plant for bulk production of this agent, though their subway attacks used the [[nerve agent]] [[sarin]] instead, because of its easy dispersal and faster-acting properties.
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
It has been recently revealed that the CIA made attempts to assassinate Fidel Castro with several Botulinum Toxin pills placed in his drinks. The attempts failed when the operatives asked out of the operation.
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>
==Biochemical mechanism of toxicity==
<!--Drug Shortage Status-->
[[image:Presynaptic_CNTs_targets.svg|thumb|right|300px|Target molecules of botulinum (BoNT) and tetanus (TeNT) toxins inside the axon terminal.[http://www.cdc.gov/ncidod/EID/vol11no10/04-1279.htm]]]
|drugShortage=
The heavy chain of the toxin is particularly important for targeting the toxin to specific types of [[axon]] terminals. The toxin must get inside the axon terminals in order to cause paralysis. Following the attachment of the toxin heavy chain to proteins on the surface of axon terminals, the toxin can be taken into neurons by [[endocytosis]]. The light chain is able to leave endocytotic vesicles and reach the [[cytoplasm]]. The light chain of the toxin has protease activity. The type A toxin proteolytically degrades the [[SNAP-25|SNAP-25 protein]], a type of [[SNARE protein]]. The SNAP-25 protein is required for the release of [[neurotransmitter]]s from the axon endings.<ref>{{cite journal |author=Foran PG, Mohammed N, Lisk GO, ''et al'' |title=Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons |journal=J. Biol. Chem. |volume=278 |issue=2 |pages=1363-71 |year=2003 |pmid=12381720 |doi=10.1074/jbc.M209821200 |url=http://www.jbc.org/cgi/content/full/278/2/1363}}</ref> Botulinum toxin specifically cleaves these SNAREs, and so prevents neuro-secretory vesicles from docking/fusing with the nerve synapse plasma membrane and releasing their neurotransmitters.
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->
Though it affects the nervous system, common nerve agent treatments (namely the injection of atropine and 2-pam-chloride) will ''increase'' mortality by enhancing botulin toxin's mechanism of toxicity. Attacks involving botulinum toxin are distinguishable from those involving nerve agent in that NBC detection equipment (such as M-8 paper or the ICAM) will not indicate a "positive" when a sample of the agent is tested. Furthermore, botulism symptoms develop relatively slowly, over several days compared to nerve agent effects, which can be instantaneous.
==Outbreaks==
On July 2, 1971 the [[FDA]] released a public warning after learning that a New York man had died and his wife had become seriously ill due to botulism after eating a can of Bon Vivant vichyssoise soup. The company began a recall of the 6,444 cans of vichyssoise soup made in the same batch as the can known to be contaminated. The FDA discovered that the company’s processing practices raised questions not only about these lots of the vichyssoise, but also about all other products packed by the company. The effectiveness check of the recall had revealed a number of swollen or otherwise suspect cans among Bon Vivant’s other products, so FDA extended the recall to include ''all'' Bon Vivant products. The FDA shut down the company’s Newark, New Jersey plant on July 7, 1971. Although only five cans of Bon Vivant soup were found to be contaminated with the [[botulin toxin]], all in the initial batch of vichyssoise recalled and part of the first 324 cans tested. The ordeal destroyed public confidence in the company’s products and the Bon Vivant name. Bon Vivant filed for bankruptcy within a month of the announcement of the recall. <ref>{{cite news |first= |last= |authorlink= |coauthors= |title=An Examination of FDA’s Recall Authority |url=http://leda.law.harvard.edu/leda/data/729/Curatolo05.html |quote=The incident did not take a toll only on the company, however. Bon Vivant did not have adequate records and controls of production lots and distribution in order to trace the products quickly. The company also did not have the finances or manpower necessary to run a successful recall program. As a result, the FDA had to seize all the Bon Vivant soup throughout the country, more than a million cans in all. FDA said the seizure occupied 125 man years of FDA time, enough for 2,000 ordinary factory inspections for preventive purposes. |publisher=[[Harvard Law School]] |date= |accessdate=2007-09-25 }}</ref>
==Treatment of botulinum poisoning==
<!--Label Display Image-->
The case fatality rate for botulinum poisoning from 1950-1996 was 15.5%, down from approximately 60% the 50-years prior. <ref>{{cite web |url=http://www.cdc.gov/ncidod/dbmd/diseaseinfo/files/botulism_manual.htm |title=Disease Listing, Botulism Manual, Additional Information | CDC Bacterial, Mycotic Diseases |accessdate=2007-08-14 |format= |work=}}</ref> Death is generally secondary to respiratory failure due to paralysis of the respiratory muscles, so treatment consists of antitoxin administration and artificial ventilation. If initiated on time, these are quite effective. Occasionally, functional recovery may take several weeks to months.
There are two primary Botulinum Antitoxins available for treatment of botulism.
* Trivalent (A,B,E) Botulinum [[Antitoxin]] is derived from equine sources utilizing whole [[antibodies]] (Fab & Fc portions). This [[antitoxin]] is available from the local health department via the [[Centers for Disease Control|CDC]].
* The second [[antitoxin]] is Heptavalent (A,B,C,D,E,F,G) Botulinum [[Antitoxin]] which is derived from "despeciated" equine IgG [[antibodies]] which have had the Fc portion cleaved off leaving the F(ab')2 portions. This is a less immunogenic [[antitoxin]] that is effective against all known strains of botulism where not contraindicated. This is available from the US Army. On June 1, 2006 the US [[Department of Health and Human Services]] awarded a $363 million contract with Cangene Corporation for 200,000 doses of Heptavalent Botulinum [[Antitoxin]] over five years for delivery into the Strategic National Stockpile beginning in 2007.<ref>{{cite web |url=http://mmrs.fema.gov/news/publichealth/2006/aug/nph2006-08-03a.aspx |title=FEMA |accessdate=2007-08-14 |format= |work=}}</ref>
==References==
{{Reflist|2}}
==External links==
<!--Category-->
* [http://www.fda.gov/fdac/features/095_bot.html A Poison that can Heal] from the [[FDA]]
* [http://health.howstuffworks.com/botox.htm How Stuff Works - Botox]
* [http://www.cosmeticdoctors.co.uk/botox.asp Botox Information from The British Association of Cosmetic Doctors]
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
Content
Overview
Botulinum toxin is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include .
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition1
Dosing Information
Dosage
Condition2
Dosing Information
Dosage
Condition3
Dosing Information
Dosage
Condition4
Dosing Information
Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Botulinum toxin in adult patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Botulinum toxin in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Botulinum toxin in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Botulinum toxin in pediatric patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Botulinum toxin in pediatric patients.
Contraindications
Condition1
Warnings
ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
Content
Description
Precautions
Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Botulinum toxin in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Botulinum toxin in the drug label.
